Lin Patrick's Form 4 filing
Processa Pharmaceuticals, Inc. (PCSA) · filed Aug 30, 2021
- Accession no.
- 0001567619-21-016470
- Filed
- Aug 30, 2021
- Trade date
- Aug 26, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $24.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lin PatrickCIK 0001799363 | Officer (Chief Business - Strategy Off) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2021 | Common Stock | PPurchaseAcquired | +4,000 | $6.02F1 | +$24,080 | 422,890 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.92 to $6.1099, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.